Posted by Michael Wonder on 18 May 2019
U.S. FDA approves Gattex (teduglutide) for children 1 year of age and older with short bowel syndrome
17 May 2019 - Gattex is the only glucagon-like peptide-2 analogue approved that improves intestinal absorption in patients with SBS who are dependent on parenteral support.
Takeda announced today that the U.S. FDA approved extending the indication of Gattex (teduglutide) for injection to paediatric patients 1 year of age and older with short bowel syndrome (SBS) who need additional nutrition or fluids from intravenous feeding (parenteral support).
In a 24-week paediatric study, Gattex helped reduce the volume of daily PS required and time spent administering PS. Some children even achieved complete freedom from PS.1 Fifty- nine paediatric patients with SBS aged 1 year through 17 years chose whether to receive Gattex or standard of care.
